deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT02467634

Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD (RADIANT)

A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Sponsor: StemCells, Inc.

Updated 6 times since 2017 Last updated: May 31, 2016 Started: Jun 30, 2015 Primary completion: May 31, 2016 Completion: May 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Based on a business decision unrelated to any safety concerns.

Listed as NCT02467634, this PHASE2 trial focuses on Age-Related Macular Degeneration and remains terminated or withdrawn. Sponsored by StemCells, Inc., it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • StemCells, Inc.
Data source: StemCells, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .